α-adrenoceptor-mediated coronary vasoconstriction is augmented during exercise in experimental diabetes mellitus

Journal of Applied Physiology

Volumn 97, Issue 1, 2004, Pages 431-438

  Setty, Srinath ^a   Sun, Wei ^a   Martinez, Rodolfo ^a   Downey, H Fred ^a   Tune, Johnathan D ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary blood flow; Myocardial oxygen consumption

Indexed keywords

ALLOXAN; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; GLUCOSE; NORADRENALIN; PHENTOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY CONSTRICTION; CORONARY SINUS; DIABETES MELLITUS; DOG; EXERCISE; FLOWMETER; GLUCOSE BLOOD LEVEL; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; INTRACORONARY INFUSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREADMILL EXERCISE; VENOUS OXYGEN TENSION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD GAS ANALYSIS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERTION; FEMALE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIUM; NOREPINEPHRINE; OXYGEN CONSUMPTION; PHENTOLAMINE; PROPRANOLOL; RECEPTORS, ADRENERGIC, ALPHA; VASOCONSTRICTION;

EID: 3042608464     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.01122.2003     Document Type: Article

References (49)

1. Altman JD, Kinn J, Duncker DJ, and Bache RJ. Effect of inhibition of nitric oxide formation on coronary blood flow during exercise in the dog. Cardiovasc Res 28: 119-124, 1994.
2. Austin CE and Chess-Williams R. Transient elevation of cardiac β-adrenoceptor responsiveness and receptor number in the streptozotocin-diabetic rat. J Auton Pharmacol 12: 205-214, 1992.
3. 1-adrenergic blockade on coronary blood flow during exercise. Circ Res 61: II36-II41, 1987.
4. Baran KW, Bache RJ, Dai XZ, and Schwartz JS. Effect of α-adrenergic blockade with prazosin on large coronary diameter during exercise. Circulation 85: 1139-1145, 1992.
5. Baumgart D, Ehring T, Kowallik P, Guth BD, Krajcar M, and Heusch G. Impact of alpha-adrenergic coronary vasoconstriction on the transmural myocardial blood flow distribution during humoral and neuronal adrenergic activation. Circ Res 73: 869-886, 1993.
6. Bernstein RD, Ochoa FY, Xu X, Forfia P, Shen W, Thompson CI, Hintze TH. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise. Circ Res 79: 840-848, 1996.
7. 2-adrenergic receptors in the coronary microcirculation. Circulation 84: 2108-2122, 1991.
8. Chilian WM, Layne SM, Easham CL, and Marcus ML. Heterogeneous microvascular coronary α-adrenergic vasoconstriction. Circ Res 64: 376-388, 1989.
9. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, and McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556, 1992.
10. 2-adrenergic blockade. Am J Physiol Heart Circ Physiol 256: H1148-H1155, 1989.
11. 1-adrenergic constriction of coronary arterioles. Am J Physiol Heart Circ Physiol 276: H1028-H1034, 1999.
12. 1-adrenergic constrictor tone varies with intensity of exercise. Med Sci Sports Exerc 28: 62-71, 1996.
13. Donatelli M, Hoffmann E, Colletti I, Andolina G, Russo V, Bucalo ML, Valenti TM, Compagno V, Cataldo MG, and Morici ML. Circulating endothelin-1 levels in type 2 diabetic patients with ischemic heart disease. Acta Diabetol 33: 246-248, 1996.
14. Downing SE, Lee JC, and Fripp RR. Enhanced sensitivity of diabetic hearts to α-adrenoceptor stimulation. Am J Physiol Heart Circ Physiol 245: H808-H813, 1983.
15. Duncker DJ and Bache RJ. Inhibition of nitric oxide production aggravates myocardial hypoperfusion during exercise in the presence of a coronary artery stenosis. Circ Res 74: 629-640, 1994.
16. Feigl EO. Neural control of coronary blood flow. J Vasc Res 35: 85-92, 1998.
17. Frisbee JC and Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1304-H1311, 2001.
18. Gaba MK, Gaba S, and Clark LT. Cardiovascular disease in patients with diabetes: clinical considerations. J Assoc Acad Minor Phys 10: 15-22, 1999.
19. Gebremedhin D, Koltai MZ, Pogatsa G, Magyar K, and Hadhazy P. Influence of experimental diabetes on the mechanical responses of canine coronary arteries: role of endothelium. Cardiovasc Res 22: 537-544, 1988.
20. Gorman MW, Tune JD, Richmond KN, and Feigl EO. Feedforward sympathetic coronary vasodilation in exercising dogs. J Appl Physiol 89: 1892-1902, 2000.
21. Gorman MW, Tune JD, Richmond KN, and Feigl EO. Quantitative analysis of feedforward sympathetic coronary vasodilation in exercising dogs. J Appl Physiol 89: 1903-1911, 2000.
22. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, and Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professions from the American Heart Association. Circulation 200: 1134-1145, 1999.
23. 1- Adrenergic constriction limits coronary flow and cardiac function in running dogs. Am J Physiol Heart Circ Physiol 250: H1117-H1126, 1986.
24. Heijnis JB and Zwieten PA. Enhanced inotropic responsiveness to alpha 1-adrenoceptor stimulation in isolated working hearts from diabetic rats. J Cardiovasc Pharmacol 20: 559-562, 1992.
25. Heusch G and Deussen A. The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog. Circ Res 53: 8-15, 1983.
26. 2-adrenoceptor-mediated vasoconstriction of large and small canine coronary arteries in vivo. J Cardiovasc Pharmacol 6: 961-968, 1984.
27. Heylinger CE, Pierce GN, Singal PK, Beamish RE, and Dhalla NS. Cardiac alpha- and beta adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res Cardiol 77: 610-618, 1982.
28. Hopfer RL, McNeill R, and Gopalakrishnan V. Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 374: 221-227, 1999.
29. Huang AH and Feigl EO. Adrenergic coronary vasoconstriction helps maintain uniform transmural blood flow distribution during exercise. Circ Res 62: 286-298, 1988.
30. 2-adrenergic coronary vasoconstriction during exercise in the ischemic heart. Circ Res 80: 196-207, 1997.
31. Koltai MZ, Jermendy G, Kiss V, Wagner M, and Pogatsa G. The effects of sympathetic stimulation and adenosine on coronary circulation and heart function in diabetes mellitus. Acta Physiol Hung 63: 119-125, 1984.
32. Latifpour J and McNeill JH. Cardiac autonomic receptors: effect of long-term experimental diabetes. J Pharmacol Exp Ther 230: 242-249, 1984.
33. Lerman A and Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation 86: III12-III19, 1992.
34. Matsunaga T, Okumura K, Ishizaka H, Tsunoda R, Tayama S, Tabuchi T, and Yasue H. Impairment of coronary blood flow regulation by endothelium-derived nitric oxide in dogs with alloxan-induced diabetes. J Cardiovasc Pharmacol 28: 60-67, 1996.
35. Miyashiro JK and Feigl EO. Feedforward control of coronary blood flow via coronary β-receptor stimulation. Circ Res 73: 252-263, 1993.
36. Morita K, Mori H, Tsujioka K, Kimura A, Ogasawara Y, Goto M, Hiramatsu O, Kajiya F, and Feigl EO. α-Adrenergic vasoconstriction reduces systolic retrograde coronary blood flow. Am J Physiol Heart Circ Physiol 273: H2746-H2755, 1997.
37. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes; protective role of arginine on endothelial dysfunction. Hypertension 31: 1047-1060, 1998.
38. Pieper GM. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 42: 204-213, 1999.
39. Seitelberger R, Guth BD, Heusch G, Lee JD, Kayayama K, and Ross J. Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res 62: 436-442, 1988.
40. Sjogren A and Edvinsson L. Vasomotor changes in isolated coronary arteries from diabetic rats. Acta Physiol Scand 134: 429-436, 1988.
41. Staib AH, Appel E, Starey F, Lindner E, Grotsch H, Palm D, and Grobecker H. Exercise induced changes of catecholamines and potassium in plasma of dogs after treatment with propranolol. Arsneimittelforschung 30: 1514-1517, 1980.
42. Takamura M, Parent R, and Lavallee M. Enhanced contribution of NO to exercise-induced coronary responses after α-adrenergic receptor blockade. Am J Physiol Heart Circ Physiol 282: H508-H515, 2002.
43. Tiefenbacher CP, DeFily DV, and Chilian WM. Requisite role cardiac myocytes in coronary α1-adrenergic constriction. Circulation 98: 9-12, 1998.
44. Tune JD, Richmond KN, Gorman MW, and Feigl EO. Role of nitric oxide and adenosine in control of coronary blood flow in exercising dogs. Circulation 101: 2942-2948, 2000.
45. Tune JD, Richmond KN, Gorman MW, and Feigl EO. Control of coronary blood flow during exercise. Exp Biol Med 227: 238-250, 2002.
46. + Channels contribute to local metabolic coronary vasodilation in experimental diabetes. Diabetes 51: 1201-1207, 2002.
47. Tune JD, Yeh C, Setty S, Zong P, and Downey HF. Coronary blood flow control is impaired at rest and during exercise in conscious diabetic dogs. Basic Res Cardiol 97: 248-257, 2002.
48. Wald M, Borda ES, and Sterin-Borda L. Alpha-adrenergic supersensitivity and decreased number of alpha-adrenoceptors in heart from acute diabetic rats. Can J Physiol Pharmacol 66: 1154-1160, 1988.
49. Zhao G, Zhang X, Smith CJ, Xu X, Ochoa M, Greenhouse D, Vogel T, Curran C, and Hintze T. Reduced coronary NO production in conscious dogs after the development of alloxan-induced diabetes. Am J Physiol Heart Circ Physiol 277: H268-H278, 1999.